We have identified a series of 1H-imidazo- [4,5-c]quinolines as selective allosteric enhancers of human A 3 adenosine receptors. Several of these compounds potentiated both the potency and maximal efficacy of agonist-induced responses and selectively decreased the dissociation of the agonist N 6 -(4-amino-3-[
observed; as for many allosteric modulators of G proteincoupled receptors, an orthosteric effect was also present. The most promising leads from the present set of analogs seem to be the 2-cyclopentyl-1H-imidazo [4,5-c] quinoline derivatives, of which the 4-phenylamino analog DU124183 had the most favorable degree of allosteric modulation versus receptor antagonism. The inhibition of forskolin-stimulated cyclic AMP accumulation in intact cells that express human A 3 receptors was employed as a functional index of A 3 receptor activation. The enhancer DU124183 caused a marked leftward shift of the concentration-response curve of the A 3 receptor agonists in the presence of antagonist and, surprisingly, a potentiation of the maximum agonist efficacy by approximately 30%. Thus, we have identified a novel structural lead for developing allosteric enhancers of A 3 adenosine receptors; such enhancers may be useful for treating brain ischemia and other hypoxic conditions.
In addition to the orthosteric ligand binding site for competitive antagonists and agonists, the A 3 adenosine receptor contains an allosteric binding site (Gao et al., 2001 ). An allosteric ligand and a competitive ligand can bind to a given receptor simultaneously and modulate the affinity of the other. In the case of the ion channel-coupled GABA A receptor, diazepam enhances the endogenous neurotransmitter GABA via an allosteric site (Macdonald and Olsen, 1994) , thus providing therapeutic efficacy, whereas the direct-acting agonists are not used clinically because of the side effects. In the ion channel-coupled nicotinic receptors, galanthamine, which is an acetylcholinesterase inhibitor as well as an allosteric modulator at nicotinic receptor sites potentiating nicotinic cholinergic neurotransmission, has recently been exGilead Sciences provided financial support for Z.-G.G.
ABBREVIATIONS:
GABA, ␥-aminobutyric acid; DU124183, 2-cyclopentyl-4-phenylamino-1H-imidazo [4,5-c] quinoline; CHO, Chinese hamster ovary; CPA, N 6 -cyclopentyladenosine; CGS15943, 5-amino-9-chloro-2-(2-furyl)-1,2,4-triazolo [1,5-c] quinazoline; NECA, 5Ј-N-ethylcarboxamidoadenosine; Cl-IB-MECA, 2-chloro-N 6 - (3-iodobenzyl)-5Ј-N-methylcarbamoyladenosine; MRS1220, N-[9-chloro-2-(2-furanyl) [1, 2, 4] triazolo [1,5-c]quinazolin-5-yl] benzeneacetamide; I-AB-MECA, N 6 -(4-amino-3-iodobenzyl)-5Ј-N-methylcarboxamidoadenosine; 5, 7, (4-(2-[7-amino-2-(2-furyl) (triazolo{2,3-a}-[1,3,5] triazin-5-ylamino]ethyl)phenol); CHAPS, 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate; DU124482, 4-cyclopentylamino-2-phenyl-1H-imidazo [4,5-c] quinoline; DU124480, 2-phenyl-4-phenyloxy-1H-imidazol [4,5-c] quinoline; DU124276, 4-chloro-1H-imidazo [4,5-c] quinoline; DU124182, 2-cyclopentyl-4-phenyloxy-1H-imidazo [4,5-c] quinoline; DU124184, 2-cyclopentyl-4-cyclopentylamino-1H-imidazo [4,5-c] quinoline; DU124483, 4-amino-2-phenyl-1H-imidazo [4,5-c] quinoline; DU124185, 4-amino-2-cyclopentyl-1H-imidazo [4,5-c] quinoline; MRS1898, (1ЈR,2ЈR,3ЈS,4ЈR,5ЈS)-4-{2-chloro-6- [(3-iodophenylmethyl) 
tensively and successfully used in clinical trials and also showed satisfactory therapeutic effects in Alzheimer's disease (Olin and Schneider, 2001) . Thus, the presence of the allosteric site provided a new target for drug discovery.
Although no allosteric modulator for a G protein-coupled receptor has been used clinically so far, several lines of evidence suggested that allosteric modulators might have advantages over classical ligands from the therapeutic point of view (Birdsall et al., 1995; Linden, 1997; Kobilka, 2000; Pin et al., 2001) . The therapeutic effects of agonists may be limited by receptor desensitization. Allosteric modulators, by potentiating the effects of the endogenous agonists, may be more selective compared with the classical agonists (Birdsall et al., 1995; Bhattacharya and Linden, 1996; Linden, 1997) . The allosteric site may not have been conserved during evolution as strictly as the orthosteric ligand binding site. Currently available muscarinic drugs show only modest subtype selectivity, probably because of the strict conservation of sequence in regions considered to bind agonists (Hulme et al., 1990) . Even if the allosteric sites of different receptor subtypes are very similar, only a small intersubtype difference in protein sequence might alter the characteristic cooperativity at one subtype over another subtype. For example, the design of subtype-selective agonists or antagonists for any single subtype of G protein-coupled muscarinic receptors has proven elusive. However, by targeting the allosteric site on muscarinic receptors, compounds with much greater subtype selectivity have been identified (Birdsall et al., 1999) . One such allosteric modulator is the alkaloid brucine, which is capable of selectively enhancing the effects of acetylcholine at only m1 receptors, whereas N-chloromethylbrucine enhances acetylcholine actions at only m3 receptors. Brucine N-oxide enhances acetylcholine binding at both m3 and m4 receptors. By targeting the allosteric site, the first subtype-selective non-amino acid-like antagonists for mGlu 5 receptors have also been recently identified (Spooren et al., 2001) .
We have recently reported that a series of 3-(2-pyridinyl)isoquinoline derivatives allosterically enhanced agonist binding at A 3 adenosine receptors (Gao et al., 2001 ). In the course of screening potential allosteric modulators for A 3 receptors, we found that a series of 1H-imidazo-[4,5-c]quinolines (Fig.  1 ), including DU124183, enhanced both agonist binding and function at A 3 receptors. Herein we describe the characteristics of allosteric modulation of A 3 adenosine receptors by these compounds employing both dissociation kinetics and a cyclic AMP functional assay in intact Chinese hamster ovary (CHO) cells expressing human A 3 adenosine receptors.
Experimental Procedures
Materials. CPA, CGS15943, NECA, Cl-IB-MECA, and MRS1220 were purchased from Sigma (St. Louis, MO Cell Culture and Membrane Preparation. CHO cells expressing recombinant human A 3 adenosine receptors were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomycin, 2 mM glutamine, and 800 g/ml geneticin. Cells were harvested by trypsinization. After homogenization and suspension, cells were centrifuged at 500g for 10 min, and the pellet was resuspended in 50 mM Tris-HCl buffer, pH 8.0, containing 10 mM MgCl 2 , 1 mM EDTA, and 0.1 mg/ml CHAPS. The suspension was homogenized with an electric homogenizer for 10 s, and was then recentrifuged at 16,000g for 20 min at 4°C. The resultant pellets were resuspended in buffer in the presence of 3 units/ml adenosine deaminase, and the suspension was stored at Ϫ80°C until the binding experiments. Striatal and forebrain tissues from Wistar rats were homogenized in ice-cold 50 mM Tris-HCl buffer, pH 7.4, using an electric homogenizer. The homogenate was centrifuged at 20,000g for 10 min at 4°C, and the pellet was washed in fresh buffer. The final pellet was stored at Ϫ80°C until the binding experiments. The protein concentration was measured using the assay of Bradford (1976) . 125 I]I-AB-MECA, in a total volume of 100 l of Tris-HCl buffer (50 mM, pH 8.0) containing 10 mM MgCl 2 , and 1 mM EDTA for 60 min. The dissociation was then initiated by the addition of 3 M Cl-IB-MECA with or without allosteric modulators. The time course of dissociation of total binding was measured by rapid filtration at appropriate time intervals. Nonspecific binding was measured after 60-min incubation in the presence of 3 M Cl-IB-MECA. Binding reactions were terminated by filtration through Whatman GF/B glass-fiber filters under reduced pressure using a MT-24 cell harvester (Brandel, Gaithersburg, MD), and radioactivity was determined using a gamma-counter (5500B; Beckman Coulter, Fullerton, CA). (Nordstedt and Fredholm, 1990; Post et al., 2000) . CHO cells that expressed recombinant human A 3 adenosine receptors were harvested by trypsinization. After centrifugation and resuspension in medium, cells were deposited in 24-well plates in volumes of 1 ml. After 24 h, the medium was removed and cells were washed three times with 1 ml of Dulbecco's modified Eagle's medium containing 50 mM HEPES, pH 7.4. Cells were then treated with agonists and/or test compounds in the presence of rolipram (10 M) and adenosine deaminase (3 units/ml). After 45 min, forskolin (10 M) was added to the medium and the incubation was continued for an additional 15 min. The reaction was terminated by removal of the supernatant, and cells were lysed upon the addition of 200 l of ice-cold 0.1 M HCl. The cell lysate was resuspended and stored at Ϫ20°C. For determination of cyclic AMP production, protein kinase A was incubated with [ 3 H]cyclic AMP (2 nM) in K 2 HPO 4 /EDTA buffer (K 2 HPO 4 , 150 mM; EDTA, 10 mM), 20 l of the cell lysate, and 30 l of 0.1 M HCl or 50 l of cyclic AMP solution (0-80 nM for standard curve). Bound radioactivity was separated by rapid filtration through Whatman GF/C filters and washed once with cold buffer. Bound radioactivity was measured by liquid scintillation counter.
Statistical Analysis. Results from cyclic AMP assay and binding parameters were analyzed by Prism software (GraphPad, San Diego, CA). IC 50 values obtained from competition curves were converted to K i values by using the Cheng and Prusoff equation (1973) . Data were expressed as mean Ϯ S.E. Table 1 ). DU124183 significantly decreased the dissociation rate, whereas the isomeric compound DU124482 influenced the rate of dissociation only slightly (Fig. 2) . The dissociation rates in the absence and presence of 10 M DU124183 were 0.056 Ϯ 0.008 and 0.030 Ϯ 0.006 min Ϫ1 , respectively, which were significantly different (p Ͻ 0.05). By comparison, the nonselective adenosine receptor antagonist CGS15943 (30 M) and the A 1 receptor enhancer of agonist action, PD81723 (30 M) did not affect the dissociation rate at A 3 receptors (Table 1 ). The dissociation rates in the absence and presence of the imidazoquinoline derivatives and the residual radioligand binding remaining after 45 min of dissociation are summarized in Table 1 . For the most potent allosteric modulators, the percentage of residual [
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125 I]I-AB-MECA binding after dissociation of 45 min was roughly twice the percentage in the absence of test compounds.
In contrast to its effect on agonist dissociation from the A 3 receptor, DU124183 and DU124482 did not influence the dissociation rate of the A 3 antagonist [
3 H]PSB-11 (Fig. 3 ). The dissociation rates (k Ϫ1 ) in the presence of DU124183 and DU124482 were 0.33 Ϯ 0.05 and 0.33 Ϯ 0.07 min Ϫ1 , respectively, which were not significantly different from the k Ϫ1 value (k Ϫ1 ϭ 0.31 Ϯ 0.04 min Ϫ1 ) in the absence of allosteric modulators (P Ͼ 0.05). (Fig. 5a ). The dissociation rates in the absence (0.14 Ϯ 0.02 min Ϫ1 ) and in the presence of 10 M DU124183 and DU124482 (0.14 Ϯ 0.03 and 0.15 Ϯ 0.02 min Ϫ1 , respectively) were not significantly different (p Ͼ 0.05). Similar to its effects on agonist dissociation, DU124183 did not influence the dissociation of [ 3 H]D-PCPX from A 1 adenosine receptors (Fig. 5b ). This contrasts with the effect of amiloride, which increased the dissociation rate of [ 3 H]DPCPX from A 1 adenosine receptors (Fig. 5b) (Fig. 6a) . The dissociation rates in the absence and (Fig. 6b) . Table 1 .
Concentration-Dependent Effect of DU124183 on
Competitive Binding of 1H-Imidazo-[4,5-c]quinolines at
The effects on affinity, as orthosteric antagonist, at human A 3 receptors also depended on the substitution patterns at the 2-, 3-, and 4-positions of the imidazoquinoline derivatives. The structure activity relationships seemed to be different from those for allosteric modulation. The most potent derivatives in competitive binding experiments were the 2-phenyl-4-phenyloxy derivative DU124480 (K i , 120 nM) and the relatively simple 4-chloro derivative DU124276 (K i , 160 nM). Among the most potent derivatives for allosteric modulation, the 2-cyclopentyl-4-phenylamino derivative DU124183 was only of intermediate affinity in the competitive binding assay. Two other derivatives, DU124182 and DU124184, which had large enhancing effects, were more potent than DU124183 in orthosteric binding. Addition of a 3-methyl group in DU124585 reduced binding affinity of the parent phenoxy derivative, DU124182, by 120-fold. Addition of a N-cyclopentyl group to a 4-amino substituent had no effect on orthosteric affinity in the case of the pair of 2-phenyl derivatives, DU124482 and DU124483, although it reduced affinity by 18-fold in the case of the pair of 2-cyclopentyl derivatives, DU124184 and DU124185. Thus, for A 3 receptor competitive binding affinity, the effects of substitution at the 2-and 4-positions were also interdependent.
Functional Assay. The dissociation kinetics can provide the clearest indication of allosteric modulation; however, the potential therapeutic effect of an allosteric agent is determined by its effect on the functional activity of agonists, including the endogenous ligand. The inhibition of forskolin- stimulated cyclic AMP accumulation in CHO cells that express human A 3 receptors was employed as a functional index of A 3 receptor activation. To further evaluate the pharmacological effects of the 1H-imidazo-[4,5-c]quinoline derivatives, we observed the effects of these compounds on the potency and efficacy of Cl-IB-MECA, a potent and selective A 3 agonist containing ribose, and MRS1898, a newly synthesized potent and selective A 3 agonist containing a rigid (N)-methanocarba ring in place of the ribose moiety (Lee et al., 2001) .
Both Cl-IB-MECA and MRS1898 inhibited forskolin-stimulated cyclic AMP accumulation in CHO cells expressing human A 3 adenosine receptors and showed similar maximal effects (approximately 50% of forskolin-stimulated cyclic AMP accumulation) (Fig. 7) . The competitive A 3 antagonist MRS1220 blocked these inhibitory effects. In contrast to the effects of A 3 agonists, DU124183 had no direct effects on forskolin-stimulated cyclic AMP production in CHO cells expressing human A 3 receptors in the absence of an A 3 agonist (Fig. 7) . The selective A 3 receptor antagonist MRS1220 (Jacobson et al., 1997) at 100 nM shifted the agonist concentration-response curves to the right but had no direct effect on cyclic AMP production or the maximum effect of agonistinduced inhibition of forskolin-stimulated cyclic AMP production. The EC 50 values of Cl-IB-MECA were 2.1 Ϯ 0.4 nM under control conditions and 440 Ϯ 60 nM in the presence of 100 nM MRS1220.
Theoretically, the allosteric enhancers should induce a leftward shift in the concentration-response curve for agonist. However, this effect might be obscured by the antagonistic effects of the 1H-imidazo-[4,5-c]quinolines, which should produce a shift to the right. To avoid this confusing effect, the effect of DU124183 on the concentration-response curve of Cl-IB-MECA was studied in the presence of 100 nM MRS1220 (ϳ100 times its K i value) to overwhelm the competitive effects of DU124183. Under this condition, DU124183 caused a marked shift to the left of the Cl-IB-MECA concentration-response curve. Besides shifting the curve for Cl-IB-MECA to the left, DU124183 also potentiated the maximum inhibitory effect of Cl-IB-MECA by up to 30% (Fig. 8a) . DU124482, which is closely related chemically, had no such effect. This phenomenon was also demonstrated when using MRS1898, a potent and selective full A 3 agonist (Fig. 8b) . The EC 50 values of A 3 agonists in the absence and presence of allosteric modulators are listed in Table 2 .
Because of the presence of adenosine deaminase in the assay system, the further demonstration of the enhancing effect of the adenosine, which also presents endogenously, by DU124183 was not possible. However, we observed the effect of DU124183 on functional effects of CADO (2-chloroadenosine), which is the moderately potent analog that is chemically closest to the endogenous adenosine. An increase of the maximum efficacy of CADO by DU124183 was also observed in the cyclic AMP functional assay (Fig. 9) . In contrast to the effect of DU124183, another allosteric modulator, VUF5455, which has been reported previously (Gao et al., 2001) , did not Fig. 7 . Agonist-induced inhibition of forskolin-stimulated cyclic AMP production in CHO cells stably transfected with human A 3 receptors. All experiments were performed in the presence of rolipram (10 M) and adenosine deaminase (3 units/ml). Forskolin (10 M) was used to stimulate cyclic AMP levels. The data shown were from one experiment performed in duplicate and are typical of three independent experiments giving similar results. The level of cyclic AMP in CHO cells expressing human A 3 receptors stimulated by 10 M forskolin was 220 Ϯ 30 nM (n ϭ 5). The maximal inhibition of forskolin-stimulated cyclic AMP accumulation was ϳ50% for agonists tested. Fig. 8 . Effect of DU124183 and DU124482 on the A 3 agonists Cl-IB-MECA-(A) and MRS1898 (B)-induced inhibition of forskolin-stimulated cyclic AMP production in CHO cells expressing human A 3 receptors. MRS1220 (100 nM) was used in the experiment to overwhelm the competitive effect by test compounds. Forskolin (10 M) was used to stimulate cyclic AMP levels. All experiments were performed in the presence of 10 M rolipram and 3 units/ml adenosine deaminase. The data are from a single experiment that was representative of three independent experiments. The EC 50 values listed in Table 2 were calculated from three independent experiments performed in duplicate.
influence the maximum efficacy of CADO (Fig. 9) , suggesting the unique mechanism of action of DU124183.
Because the 1H-imidazo-[4,5-c]quinolines have both antagonistic and allosteric enhancing effects, the use of an antagonist in functional assays is a useful means of discriminating enhancing from antagonistic functional effects of these compounds. However, the addition of antagonist in the assay system might obscure the important question of whether this class of compounds will functionally enhance signaling by adenosine receptor agonists through A 3 receptors in an antagonist-free environment. Hence, additional functional cyclic AMP assays in the absence of the A 3 receptor antagonist were performed. As shown in Fig. 10 , one of the enhancers, DU124183, shifted the dose-response curves of A 3 receptor agonists to the right but increased the maximum effects, consistent with the mixed allosteric and competitive effects of this compound and also consistent with the enhancement of the maximum efficacy A 3 agonists in the presence of a competitive antagonist. By contrast, VUF5455 did not influence the maximum efficacy (Fig. 10) .
Discussion
In the present study, we demonstrated for the first time that the imidazoquinoline derivative DU124183 selectively decreased the dissociation rate of the agonist radioligand from human A 3 adenosine receptors. Furthermore, and surprisingly, this derivative increased the maximum efficacy as well as the potency of A 3 agonists in a cyclic AMP functional assay in intact CHO cells expressing human A 3 receptors. This compound modified the intrinsic efficacy of the orthosteric ligands without having any intrinsic efficacy of its own; thus, we have identified a novel structural lead for developing allosteric enhancers of A 3 adenosine receptors.
With this set of analogs, it was possible to discern structure activity relationship patterns for the allosteric modulation of A 3 agonist effects. Additional analogs would need to be synthesized and tested to verify these tentative conclusions. Substitution at the 2-and 4-positions, however, was possible; in some cases, this resulted in enhancement of allosteric modulation. Both amino and aryl ether substituents were molpharm.aspetjournals.org tolerated at the 4-position. A 4-phenylamino group was roughly equivalent to a 4-phenylether group in its positive effect on allosteric modulation. The effects of substitution at the 2-and 4-positions were interdependent. In the case of 4-cyclopentylamino substitution, the substituent at the 2-position may be various bulky groups. In the case of 4-phenylamino-or 4-phenyloxy-substition, the substituent at the 2-position may be cyclopentyl but not phenyl. A 3-methyl group precluded allosteric modulation by the imidazoquinoline derivative DU124182. The most promising leads from the present set of analogs seem to be the 2-cyclopentyl-1H-imidazo[4,5-c]quinoline derivatives DU124182, DU124183, and DU124184. Of these analogs, DU124183 had the most favorable degree of allosteric modulation versus receptor antagonism. The compound DU124482, structurally close to DU124183, influenced the agonist dissociation rate only slightly. Furthermore, in contrast to DU124183, DU124482 decreased the maximum efficacy of agonists in the cyclic AMP functional assay without affecting agonist potency, suggesting the chemical specificity of these effects. It is interesting that the reversal of positions of the phenyl group and cyclopentyl groups resulted in an almost completely different modulatory activity.
These imidazoquinoline derivatives were first reported as antagonists of A 1 and A 2A receptors (van Galen et al., 1991) . The imidazoquinoline analogs were tested in competitive binding assays at human A 3 receptors, and K i values ranging from 120 nM to 101 M were observed; as for many allosteric modulators of GPCRs, an orthosteric competitive effect was also present. One of the compounds, DU124482, was suggested to be a selective A 1 receptor antagonist (van Galen et al., 1991) ; the present study further confirmed this selectivity by virtue of weak affinity at A 3 receptors.
Allosteric modulation of adenosine receptors has been demonstrated in A 1 , A 2A , and A 3 adenosine receptors (Bruns and Fergus, 1990; Gao and IJzerman, 2000; Gao et al., 2001 ). Positive allosteric modulators at G protein-coupled receptors have been identified in both A 1 and A 3 adenosine receptors (Bruns and Fergus, 1990; Gao et al., 2001 ). However, those modulators increased the agonist potency only in binding and functional assays without affecting the maximal response. For example, the allosteric enhancer PD81723 increased the potency of the A 1 receptor agonist CPA without influencing its maximum effect (Bruns and Fergus, 1990) . Similarly, the isoquinoline derivative VUF5455 increased the potency of A 3 agonists but did not affect the maximum efficacy (Gao et al., 2001) . These effects can be described a ternary allosteric model in which both the orthosteric and allosteric ligands bind to the receptor simultaneously and modulate reciprocally. In the case of DU124183 and DU124482, it might be more complex. Recently, Hall (2000) described an extension of the two-state model of receptor activation to account for the allosteric modulators affecting the agonist affinity as well as the intrinsic efficacy of agonists. In that model, it was suggested that the most suitable assay system may be one with very low receptor expression in which even highly efficacious agonists are unable to fully activate the signal transduction cascade (Hall, 2000) . Fortuitously, in our cyclic AMP functional assay system, none of the A 3 agonists tested inhibited forskolin-stimulated cyclic AMP accumulation by more than approximately 50 to 60%. This less-than-complete inhibition made the cyclic AMP assay an ideal model for the characterization of the functional aspects of the allosteric modulators, especially the characterization of the maximum effect in the presence of allosteric modulators.
Similar to the present results demonstrated in the A 3 adenosine receptor, it has recently been reported that two chemical series of compounds, including Ro 01-6128, act as positive allosteric modulators for mGlu1 receptors (Knoflach et al., 2001) , and 2,6-di-tert-butyl-4-(3-hydroxy-2Ј,2Ј-dimethyl-propyl)phenol (CGP7930) (Urwyler et al., 2001 ) as allosteric modulators for GABA B receptors. These allosteric modulators also increased both the affinity and the maximum efficacy. However, Litschig et al. (1999) reported that an allosteric modulator for the mGlu1 receptor, 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester, decreased the efficacy of glutamate in stimulating phosphoinositide hydrolysis without affecting its potency.
The present results show that there were distinct structural requirements for allosteric enhancement of A 3 adenosine receptor binding, and these requirements were different from those for competitive A 3 antagonistic activity. For example, DU124183 was 3-fold less potent than DU124482 but it was more potent than DU124482 in its allosteric enhancing effect. It seems that the structure-activity relationships for allosteric enhancement are separable from those for competitive antagonism, suggesting that it may be possible to discover compounds with improved enhancing activity that lack antagonist activity. Nevertheless, in the present study, in a functional assay, the efficacy-enhancing effects of DU124183 were evident at high concentrations of agonist and even in the absence of the antagonist MRS1220.
In summary, we identified a new chemical series of compounds as allosteric enhancers for A 3 adenosine receptors. The 2-cyclopentyl-4-phenylamino analog DU124183 potentiated both the potency and maximal efficacy of an agonistinduced response. Allosteric enhancers of A 3 adenosine receptors may be useful for treating ischemia and other conditions involving local energy deficits, and the unusual dual effects on adenosine receptor activation might open a new route in development of drugs for the ischemic diseases.
